Testing for molecular residual disease was able to identify patients with early-stage colorectal cancer who are most likely to benefit from adjuvant chemotherapy.
Patients with stage IIA and IIB esophageal squamous cell carcinoma with lymphovascular invasion but negative lymph nodes do not benefit. The study was published as a preprint and has not yet been peer reviewed.
Eagerly awaited results show for the first time, from a prospective trial, that women with multiple breast cancer foci can safely undergo breast-conserving therapy, with low local recurrence rates.
A study of tumor microenvironments suggests that breast tumors in Black women may have a stronger prometastatic response to neoadjuvant chemotherapy than tumors in White women.